16 September 2026 editorial review · Item
Lilly Tempo connected-insulin platform: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Lilly Tempo connected-insulin platform
Scope and findings:
- Read manufacturer/Welldoc FAQ: platform ends by end2026; no new data to Insights after July27; export triggers read-only mode then account deletion after30days. GUDID distribution-end November25 is a separate device field, not platform shutdown date. Homepage redirect does not itself verify withdrawal.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.